

Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer

Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of James Wentworth, PhD, MBA, as Chief Business Officer (CBO) and member of the executive management team, effective immediately. Dr. Wentworth will be responsible for developing, leading, and implementing Transgene’s business, corporate development and partnering strategies.

Alessandro Riva, MD, Chairman and CEO of Transgene, comments: *“I am very pleased to welcome James, at a pivotal time for Transgene as we seek to develop novel cancer immunotherapies including an individualized neoantigen cancer vaccine. Our business development strategy will be crucial to achieving our goals, and James’ significant experience and knowledge will be invaluable as we continue to build our strong track record of successful collaborations.”*

Dr. Wentworth brings over fifteen years’ experience working in the pharma and biotech industry. He joins Transgene following increasing responsibility spanning business development, strategy and commercial roles. Most recently, James was Director, Business Development and Strategy at Adaptimmune, a NASDAQ-listed biotechnology company focused on developing T-cell receptor (TCR)-based cell therapies for solid tumors. His responsibilities included strategic pharma partnering, collaborations and transactions, corporate development projects, commercial strategy development and he also led the company’s competitive intelligence function.

Prior to Adaptimmune, James worked with pre-commercial Biotech companies at inVentiv Health (now Syneos Health) and held strategic roles at Shire, contributing to product development, post M&A integration, and managing commercial launches in European markets for ViroPharma Europe.

James holds a BSc Hons degree in Pharmacology and a PhD in Pharmacology both from the University of Bristol and an MBA from the International Institute for Management Development (IMD), Lausanne, Switzerland.

Dr. James Wentworth, Chief Business Officer, said: *“It is an honor to be joining Transgene at this exciting time and to work alongside the outstanding executive team to contribute to Transgene’s success. The company has achieved many important milestones over the past year, and I am excited to help deliver its growth strategy through further partnerships and collaborations. Transgene is uniquely positioned with its innovative technology and platform offering, and together with the promising emerging data for its portfolio of clinical-stage immunotherapies, has the potential to address major medical needs in the treatment of solid tumors and to transform patients’ lives.”*

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Company's clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the *myvac*[®] platform, TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO[®] viral backbone.

With Transgene's *myvac*[®] platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The *myvac*[®] approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO[®], Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Additional information about Transgene is available at: www.transgene.fr

Follow us on social media: X (previously-Twitter): [@TransgeneSA](https://twitter.com/TransgeneSA) – LinkedIn: [@Transgene](https://www.linkedin.com/company/transgene)

Contacts

Transgene:

Lucie Larguier

VP, Corporate Communications & IR

+33 (0)3 88 27 91 04

investorrelations@transgene.fr

Media: MEDISTRAVA

Frazer Hall /Sylvie Berrebi

+44 (0)203 928 6900

transgene@medistrava.com

Disclaimer

This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (<http://www.amf-france.org>) or on Transgene's website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.